Quick Answer
Beam Therapeutics Inc. reported Net Income Loss of -$79.99 million for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +78.8% in Net Income Loss from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$13.61 million | Q2 2019: -$17.86 million | Q3 2019: -$19.01 million | Q1 2020: -$30.46 million | Q2 2020: -$34.22 million | Q3 2020: -$34.45 million | Q1 2021: -$201.56 million | Q2 2021: -$76.25 million | Q3 2021: -$28.12 million | Q1 2022: -$69.21 million | Q2 2022: -$71.95 million | Q3 2022: -$109.58 million | Q1 2023: -$96.46 million | Q2 2023: -$82.78 million | Q3 2023: -$96.09 million | Q1 2024: -$98.67 million | Q2 2024: -$91.05 million | Q3 2024: -$96.67 million | Q1 2025: -$109.27 million | Q2 2025: -$102.29 million | Q3 2025: -$112.73 million.
- Over the full 7 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Net Income Loss has declined by 2.1%.
- Historical annual values: Fiscal year 2025: -$79.99 million | Fiscal year 2024: -$376.74 million | Fiscal year 2023: -$132.53 million | Fiscal year 2022: -$289.09 million | Fiscal year 2021: -$370.64 million | Fiscal year 2020: -$194.59 million | Fiscal year 2019: -$78.33 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: